What is BenchSci?
BenchSci, founded in 2015 and headquartered in Toronto, Ontario, is a prominent software provider dedicated to enhancing antibody selection for scientific research. The company's platform is engineered to streamline and optimize the complex process of choosing the right antibodies, a critical component in many biological and medical studies. By leveraging advanced technology, BenchSci aims to accelerate discovery and improve the reliability of research outcomes, positioning itself as an indispensable tool for scientists globally.
How much funding has BenchSci raised?
BenchSci has raised a total of $163M across 4 funding rounds:
Series A
$8M
Series B
$22M
Series C
$63M
Series D
$70M
Series A (2018): $8M, investors not publicly disclosed
Series B (2020): $22M led by Fidelity Investments
Series C (2022): $63M supported by Technology Crossover Ventures and Inovia
Series D (2023): $70M featuring Inovia, Generation Investment Management, and Technology Crossover Ventures
Key Investors in BenchSci
Fidelity Investments
Fidelity Investments is a financial services firm offering a wide array of investment, wealth management, and retirement planning solutions. They provide access to investment products, financial planning resources, and trading platforms, supporting individual investors and institutions in managing and growing their wealth.
Technology Crossover Ventures
Technology Crossover Ventures (TVC) is a venture capital firm established in 1995, specializing in acquisitions, mergers, and recapitalization for technology companies. Based in Menlo Park, California, TVC focuses on supporting the growth and strategic development of its portfolio companies.
Inovia
iNovia Capital, founded in 2007 and based in Montreal, Canada, is a full-stack venture firm that partners with founders to build global technology companies. The firm aims to transform venture capital by prioritizing investment in people and fostering enduring businesses.
What's next for BenchSci?
The recent major strategic investment in BenchSci signals a strong confidence in its growth trajectory and market potential. This infusion of capital is expected to fuel further innovation in its software solutions, expand its market reach, and potentially support strategic acquisitions or partnerships. As BenchSci continues to mature, its focus will likely remain on deepening its impact within the scientific research community, driving efficiency, and enabling breakthroughs through superior antibody selection tools.
See full BenchSci company page
